Clinical Trial

Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2024 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
1. To explore the predictive value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population; 2. To evaluate the prognostic value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06479460
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Breast Cancer, Neoadjuvant, HER2-positive Breast Cancer, Circulating Tumor DNA
Enrollment 50 participants
Start Date 2024-03-08
Primary Completion 2025-05-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-24